Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
NCT ID: NCT00036205
Last Updated: 2007-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
984 participants
INTERVENTIONAL
2000-08-31
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
NCT00036218
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
NCT00058838
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
NCT00866502
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
NCT04875962
SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT00269516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sumanirole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Modified Hoehn and Yahr Scale Stages 1-4
* Age over 30 years
* Previous participation in prior sumanirole studies
Exclusion Criteria
* Unstable dose of CNS active therapies (eg, hypnotics, antidepressants, anxiolytics) within the last 30 days
* Atypical Parkinson's syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases
* Dementia
* History of active epilepsy within the past year
* Significant liver disease with defined laboratory criteria
* Significant renal disease with defined laboratory criteria
* Certain cardiac conditions
* Electroconvulsive therapy in the previous 90 days
* Subjects participating in other drug studies or receiving other investigational drugs within previous 30 days
* Positive pregnancy test at Screen
* Unwillingness to use adequate contraceptive methods
* Lactating women
* History of stereotaxic brain surgery
* Malignant melanoma or history of treated melanoma
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Peoria, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Concord, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Irvine, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Loma Linda, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Oceanside, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Luis Obiapo, California, United States
Pfizer Investigational Site
Sunnyvale, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Englewood, Colorado, United States
Pfizer Investigational Site
Fairfield, Connecticut, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
Trumbull, Connecticut, United States
Pfizer Investigational Site
Wilmington, Delaware, United States
Pfizer Investigational Site
Boca Raton, Florida, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Fort Lauderdale, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Maitland, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Naples, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Palm Beach Gardens, Florida, United States
Pfizer Investigational Site
Plantation, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
St. Petersburg, Florida, United States
Pfizer Investigational Site
Tallahassee, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Decatur, Georgia, United States
Pfizer Investigational Site
Marietta, Georgia, United States
Pfizer Investigational Site
Savannah, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Elkhart, Indiana, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
Dubuque, Iowa, United States
Pfizer Investigational Site
Kansas City, Kansas, United States
Pfizer Investigational Site
Lenexa, Kansas, United States
Pfizer Investigational Site
Crestview Hills, Kentucky, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
Lake Charles, Louisiana, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Elkridge, Maryland, United States
Pfizer Investigational Site
Frederick, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Bingham Farms, Michigan, United States
Pfizer Investigational Site
Farmington Hills, Michigan, United States
Pfizer Investigational Site
Grand Rapids, Michigan, United States
Pfizer Investigational Site
Royal Oak, Michigan, United States
Pfizer Investigational Site
Traverse City, Michigan, United States
Pfizer Investigational Site
Fridley, Minnesota, United States
Pfizer Investigational Site
Golden Valley, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, United States
Pfizer Investigational Site
Lee's Summit, Missouri, United States
Pfizer Investigational Site
Salisbury, Missouri, United States
Pfizer Investigational Site
Springfield, Missouri, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Lebanon, New Hampshire, United States
Pfizer Investigational Site
Morristown, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Manhasset, New York, United States
Pfizer Investigational Site
Mineola, New York, United States
Pfizer Investigational Site
Mount Vernon, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Asheville, North Carolina, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Canfield, Ohio, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Eugene, Oregon, United States
Pfizer Investigational Site
Norristown, Pennsylvania, United States
Pfizer Investigational Site
Sellersville, Pennsylvania, United States
Pfizer Investigational Site
Upland, Pennsylvania, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Burlington, Vermont, United States
Pfizer Investigational Site
Charlottesville, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Bellevue, Washington, United States
Pfizer Investigational Site
Wenatchee, Washington, United States
Pfizer Investigational Site
Marshfield, Wisconsin, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
Buenos Aires, Barcelona, Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Mar del Plata, Buenos Aires, Argentina
Pfizer Investigational Site
Buenos Aires, Buenos Aires F.D., Argentina
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Bogotá, D.C., Colombia
Pfizer Investigational Site
Carolina, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M27600011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.